PZ0369
PF-04217329
≥98% (HPLC)
别名:
2-[3-[[[[4-(1H-Pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]-acetic acid 1-methylethyl ester, Isopropyl 2-[3-[[[[4-(1H-pyrazol-1-yl)phenyl]methyl](pyridin-3-ylsulfonyl)amino]methyl]phenoxy]acetate, PF 04217329, Taprenepag isopropyl
InChI
1S/C27H28N4O5S/c1-21(2)36-27(32)20-35-25-7-3-6-23(16-25)19-30(37(33,34)26-8-4-13-28-17-26)18-22-9-11-24(12-10-22)31-15-5-14-29-31/h3-17,21H,18-20H2,1-2H3
InChI key
NVPXUFQLKWKBHK-UHFFFAOYSA-N
SMILES string
O=S(N(CC1=CC=C(N2N=CC=C2)C=C1)CC3=CC=CC(OCC(OC(C)C)=O)=C3)(C4=CC=CN=C4)=O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
room temp
Quality Level
Biochem/physiol Actions
PF-04217329 is a selective and potent prostaglandin EP2 receptor agonist. PF-04217329 is an ocular bioavailable isopropyl ester prodrug of CP-544326 (active acid metabolite).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Gina M Yanochko et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 30(5), 429-439 (2014-04-12)
Taprenepag isopropyl is an EP2 receptor agonist that is in development for the treatment of glaucoma. Iritis, photophobia, and increased corneal thickness observed in a Phase 2 clinical trial with taprenepag isopropyl were not previously observed in topical ocular toxicity
Ganesh Prasanna et al.
Experimental eye research, 93(3), 256-264 (2011-03-08)
Better control of intraocular pressure (IOP) is the most effective way to preserve visual field function in glaucomatous patients. While prostaglandin FP analogs are leading the therapeutic intervention for glaucoma, new target classes also are being identified with new lead
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持